AAPL341.15+1.65 (+0.49%) ▲|ABBV286.36-2.60 (-0.90%) ▼|ABT99.16-3.29 (-3.21%) ▼|ACN239.63+0.51 (+0.21%) ▲|ADBE256.33-0.40 (-0.16%) ▼|AMAT407.98+3.00 (+0.74%) ▲|AMD542.98+8.24 (+1.54%) ▲|AMGN436.48-2.46 (-0.56%) ▼|AMT179.77-3.79 (-2.06%) ▼|AMZN260.04-2.59 (-0.99%) ▼|AVGO333.80-0.57 (-0.17%) ▼|AXP321.75+3.41 (+1.07%) ▲|BA191.87+1.40 (+0.74%) ▲|BAC50.73+0.09 (+0.18%) ▲|BKNG157.99-5.93 (-3.62%) ▼|BLK1,132.51+3.83 (+0.34%) ▲|BMY61.25-0.44 (-0.71%) ▼|BNY145.28+1.03 (+0.71%) ▲|BRK-B541.72+1.90 (+0.35%) ▲|C122.60+0.09 (+0.07%) ▲|CAT734.01+8.77 (+1.21%) ▲|CL93.58-0.96 (-1.02%) ▼|CMCSA21.80-0.57 (-2.53%) ▼|COF209.72+8.16 (+4.05%) ▲|COP146.24+0.29 (+0.20%) ▲|COST990.15-4.46 (-0.45%) ▼|CRM241.54-0.90 (-0.37%) ▼|CSCO107.36+0.65 (+0.60%) ▲|CVS94.10-0.66 (-0.69%) ▼|CVX226.91+1.20 (+0.53%) ▲|DE628.79-3.41 (-0.54%) ▼|DHR228.90+4.66 (+2.08%) ▲|DIS110.58-1.09 (-0.98%) ▼|DUK121.17-0.16 (-0.13%) ▼|EMR161.89+1.43 (+0.89%) ▲|FDX298.94+0.18 (+0.06%) ▲|GD345.69+1.25 (+0.36%) ▲|GE304.97+5.10 (+1.70%) ▲|GEV921.39+31.06 (+3.49%) ▲|GILD152.75-3.76 (-2.40%) ▼|GM75.77-1.32 (-1.71%) ▼|GOOG327.00-9.40 (-2.79%) ▼|GOOGL331.07-9.21 (-2.71%) ▼|GS891.05+6.24 (+0.70%) ▲|HD313.58-1.53 (-0.48%) ▼|HON214.76+1.44 (+0.67%) ▲|IBM244.12+2.20 (+0.91%) ▲|INTC91.80+0.11 (+0.11%) ▲|INTU333.34-1.96 (-0.58%) ▼|ISRG418.37-19.63 (-4.48%) ▼|JNJ255.38-3.99 (-1.54%) ▼|JPM333.44-1.82 (-0.54%) ▼|KO92.86-0.64 (-0.68%) ▼|LIN500.09-1.80 (-0.36%) ▼|LLY1,266.98-16.68 (-1.30%) ▼|LMT548.71+0.00 (+0.00%) ▲|LOW195.92-1.36 (-0.69%) ▼|LRCX265.10+1.65 (+0.63%) ▲|MA621.11+0.69 (+0.11%) ▲|MCD244.10-2.42 (-0.98%) ▼|MDLZ63.16-0.83 (-1.30%) ▼|MDT93.77-0.87 (-0.91%) ▼|META704.66+10.41 (+1.50%) ▲|MMM170.67-0.70 (-0.41%) ▼|MO74.12-0.53 (-0.70%) ▼|MRK148.65+0.35 (+0.24%) ▲|MS181.69+1.29 (+0.72%) ▲|MSFT529.51-2.36 (-0.44%) ▼|MU904.87+8.80 (+0.98%) ▲|NEE78.56-0.30 (-0.38%) ▼|NFLX65.92-2.77 (-4.03%) ▼|NKE37.57-0.32 (-0.83%) ▼|NOW151.90+2.36 (+1.57%) ▲|NVDA218.12+1.65 (+0.76%) ▲|ORCL129.46-1.68 (-1.28%) ▼|PEP134.35+0.33 (+0.25%) ▲|PFE29.88-0.24 (-0.78%) ▼|PG157.97-1.35 (-0.85%) ▼|PLTR196.90+4.30 (+2.23%) ▲|PM196.25-3.66 (-1.83%) ▼|QCOM176.25+0.54 (+0.31%) ▲|RTX191.35-1.99 (-1.03%) ▼|SBUX98.62-0.75 (-0.75%) ▼|SCHW91.23+0.34 (+0.37%) ▲|SO90.40-0.32 (-0.35%) ▼|SPG205.54-1.46 (-0.70%) ▼|T22.01-1.41 (-6.02%) ▼|TMO690.98+3.61 (+0.53%) ▲|TMUS153.72-4.04 (-2.56%) ▼|TSLA386.41+12.70 (+3.40%) ▲|TXN282.60+4.82 (+1.73%) ▲|UBER68.42-0.52 (-0.75%) ▼|UNH417.07-2.19 (-0.52%) ▼|UNP290.03+2.42 (+0.84%) ▲|UPS99.03+0.51 (+0.51%) ▲|USB59.03-0.06 (-0.10%) ▼|V407.04+0.47 (+0.12%) ▲|VZ43.39-1.16 (-2.59%) ▼|WFC81.86-0.34 (-0.41%) ▼|WMT117.51-0.34 (-0.29%) ▼|XOM177.96+0.10 (+0.06%) ▲|AAPL341.15+1.65 (+0.49%) ▲|ABBV286.36-2.60 (-0.90%) ▼|ABT99.16-3.29 (-3.21%) ▼|ACN239.63+0.51 (+0.21%) ▲|ADBE256.33-0.40 (-0.16%) ▼|AMAT407.98+3.00 (+0.74%) ▲|AMD542.98+8.24 (+1.54%) ▲|AMGN436.48-2.46 (-0.56%) ▼|AMT179.77-3.79 (-2.06%) ▼|AMZN260.04-2.59 (-0.99%) ▼|AVGO333.80-0.57 (-0.17%) ▼|AXP321.75+3.41 (+1.07%) ▲|BA191.87+1.40 (+0.74%) ▲|BAC50.73+0.09 (+0.18%) ▲|BKNG157.99-5.93 (-3.62%) ▼|BLK1,132.51+3.83 (+0.34%) ▲|BMY61.25-0.44 (-0.71%) ▼|BNY145.28+1.03 (+0.71%) ▲|BRK-B541.72+1.90 (+0.35%) ▲|C122.60+0.09 (+0.07%) ▲|CAT734.01+8.77 (+1.21%) ▲|CL93.58-0.96 (-1.02%) ▼|CMCSA21.80-0.57 (-2.53%) ▼|COF209.72+8.16 (+4.05%) ▲|COP146.24+0.29 (+0.20%) ▲|COST990.15-4.46 (-0.45%) ▼|CRM241.54-0.90 (-0.37%) ▼|CSCO107.36+0.65 (+0.60%) ▲|CVS94.10-0.66 (-0.69%) ▼|CVX226.91+1.20 (+0.53%) ▲|DE628.79-3.41 (-0.54%) ▼|DHR228.90+4.66 (+2.08%) ▲|DIS110.58-1.09 (-0.98%) ▼|DUK121.17-0.16 (-0.13%) ▼|EMR161.89+1.43 (+0.89%) ▲|FDX298.94+0.18 (+0.06%) ▲|GD345.69+1.25 (+0.36%) ▲|GE304.97+5.10 (+1.70%) ▲|GEV921.39+31.06 (+3.49%) ▲|GILD152.75-3.76 (-2.40%) ▼|GM75.77-1.32 (-1.71%) ▼|GOOG327.00-9.40 (-2.79%) ▼|GOOGL331.07-9.21 (-2.71%) ▼|GS891.05+6.24 (+0.70%) ▲|HD313.58-1.53 (-0.48%) ▼|HON214.76+1.44 (+0.67%) ▲|IBM244.12+2.20 (+0.91%) ▲|INTC91.80+0.11 (+0.11%) ▲|INTU333.34-1.96 (-0.58%) ▼|ISRG418.37-19.63 (-4.48%) ▼|JNJ255.38-3.99 (-1.54%) ▼|JPM333.44-1.82 (-0.54%) ▼|KO92.86-0.64 (-0.68%) ▼|LIN500.09-1.80 (-0.36%) ▼|LLY1,266.98-16.68 (-1.30%) ▼|LMT548.71+0.00 (+0.00%) ▲|LOW195.92-1.36 (-0.69%) ▼|LRCX265.10+1.65 (+0.63%) ▲|MA621.11+0.69 (+0.11%) ▲|MCD244.10-2.42 (-0.98%) ▼|MDLZ63.16-0.83 (-1.30%) ▼|MDT93.77-0.87 (-0.91%) ▼|META704.66+10.41 (+1.50%) ▲|MMM170.67-0.70 (-0.41%) ▼|MO74.12-0.53 (-0.70%) ▼|MRK148.65+0.35 (+0.24%) ▲|MS181.69+1.29 (+0.72%) ▲|MSFT529.51-2.36 (-0.44%) ▼|MU904.87+8.80 (+0.98%) ▲|NEE78.56-0.30 (-0.38%) ▼|NFLX65.92-2.77 (-4.03%) ▼|NKE37.57-0.32 (-0.83%) ▼|NOW151.90+2.36 (+1.57%) ▲|NVDA218.12+1.65 (+0.76%) ▲|ORCL129.46-1.68 (-1.28%) ▼|PEP134.35+0.33 (+0.25%) ▲|PFE29.88-0.24 (-0.78%) ▼|PG157.97-1.35 (-0.85%) ▼|PLTR196.90+4.30 (+2.23%) ▲|PM196.25-3.66 (-1.83%) ▼|QCOM176.25+0.54 (+0.31%) ▲|RTX191.35-1.99 (-1.03%) ▼|SBUX98.62-0.75 (-0.75%) ▼|SCHW91.23+0.34 (+0.37%) ▲|SO90.40-0.32 (-0.35%) ▼|SPG205.54-1.46 (-0.70%) ▼|T22.01-1.41 (-6.02%) ▼|TMO690.98+3.61 (+0.53%) ▲|TMUS153.72-4.04 (-2.56%) ▼|TSLA386.41+12.70 (+3.40%) ▲|TXN282.60+4.82 (+1.73%) ▲|UBER68.42-0.52 (-0.75%) ▼|UNH417.07-2.19 (-0.52%) ▼|UNP290.03+2.42 (+0.84%) ▲|UPS99.03+0.51 (+0.51%) ▲|USB59.03-0.06 (-0.10%) ▼|V407.04+0.47 (+0.12%) ▲|VZ43.39-1.16 (-2.59%) ▼|WFC81.86-0.34 (-0.41%) ▼|WMT117.51-0.34 (-0.29%) ▼|XOM177.96+0.10 (+0.06%) ▲|
10.7 C
New York
Wednesday, October 21, 2026

Tag: clinical trial

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI...

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards

Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants.

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

 Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time           SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call

DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on Wednesday, August 6, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, July 15, 2025 /PRNewswire/ -- BioVaxys...

BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys...

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial